NCT06369467 is a Phase 1 clinical trial of linvoseltamab in Food Allergy, sponsored by Regeneron Pharmaceuticals.

Who is sponsoring NCT06369467?

NCT06369467 is sponsored by Regeneron Pharmaceuticals.

What drugs are being tested in NCT06369467?

Interventions in NCT06369467: linvoseltamab, dupilumab.

What condition does NCT06369467 study?

NCT06369467 studies Food Allergy.

Is NCT06369467 still recruiting?

NCT06369467 is currently recruiting now. Last updated 13 November 2025.

Last reviewed 2025-11-13 · How we verify

NCT06369467

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

Recruiting now Phase 1 Last updated 13 November 2025

What this trial tests

Phase 1 trial testing linvoseltamab in Food Allergy in 6 participants. Currently enrolling.

Timeline

17 May 2024

Primary endpoint
28 March 2028

28 March 2028

Quick facts

Lead sponsor	Regeneron Pharmaceuticals
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	17 May 2024
Primary completion	28 March 2028
Estimated completion	28 March 2028
Sites	7 locations across United States, Spain

Drugs / interventions tested

linvoseltamab (LINVOSELTAMAB) — full drug profile →
dupilumab (DUPILUMAB) — full drug profile →

Conditions studied

Food Allergy — all drugs for Food Allergy →

Sponsor

Regeneron Pharmaceuticals — full company profile →

Who can join

Adults 18 to 50, any sex, with Food Allergy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is researching an experimental drug called linvoseltamab combined with another drug called dupilumab. The study is looking at patients who have severe IgE-mediated food allergy. If the patient has an allergy, the body's defense system (immune system) overreacts to an allergen (eg, certain foods like peanuts, milk, shellfish) by making antibodies called IgE. An antibody is a protein that allows the immune system to find and fight off things the body does not recognize (allergens). IgE antibodies are sent out by cells like plasma cells. These antibodies and allergens bind to other cells that send out chemicals, causing an allergic reaction. The aim of the study is to see what side effects happen when linvoseltamab is combined with dupilumab. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * Does linvoseltamab combined with dupilumab affect other types of antibodies in the blood at different times * How much study drug(s) is in the blood at different times

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advances in Shellfish Allergy Therapy: From Current Approaches to Future Strategies.
Heidari S, Ruethers T, Karnaneedi S, Yin LWS, et al · · 2025 · cited 4× · PMID 40668267 · DOI 10.1007/s12016-025-09077-8

Verify or expand the search:

Other recruiting trials for Food Allergy

Currently open trials in the same condition.

NCT07210320 — PK/PD Study of IN-001 Sublingual Spray in Healthy Adults · Phase 1 · recruiting
NCT06943534 — Omalizumab Weight-Based Dosing Efficacy Trial · Phase 2 · recruiting
NCT06872996 — Trophallergen Prick Tests (PT) : Influence of Food Sample Shelf Life on the Reproducibility of PT Results · NA · recruiting
NCT06529913 — Environmental Exposure to Heavy Metals, Nanoparticles, and Emergent Contaminants and Risk of Allergic Diseases · NA · recruiting
NCT06558526 — Pectin Intervention Study and Long-term Follow-up in Lipid Transfer Proteins Allergic Patients · NA · recruiting

Other Regeneron Pharmaceuticals trials

Trials by the same sponsor.

NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
NCT07526116 — A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adul · Phase 1 · not yet recruiting
NCT07527923 — First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis · Phase 1 · not yet recruiting
NCT07527910 — A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD · Phase 2 · not yet recruiting
NCT07477704 — A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemi · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06369467 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Regeneron Pharmaceuticals
Last refreshed: 13 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06369467.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing